1/15/2013

GlaxoSmithKline has filed for FDA approval for albiglutide, its once-weekly diabetes drug. Albiglutide is an injectable GLP-1 drug and belongs to the same class as Novo Nordisk's Victoza and Bristol-Myers Squibb and AstraZeneca's Byetta and Bydureon.

Full Story:
Reuters

Related Summaries